77.3 Reasons That May Make GlaxoSmithKline plc A Buy

Royston Wild reveals why shares in GlaxoSmithKline plc (LON: GSK) look set to surge higher.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am explaining why I believe shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are set to move higher owing to its improving outlook as a reliable and generous dividend generator.

The perfect tonic for healthy dividend growth

GlaxoSmithKline is one of the more lucrative dividend bets in the pharmaceuticals space, underpinned by strong financials and a promising earnings outlook. The company is expected to build its full-year dividend to 77.3p per share in 2013, and I expect payouts to continue rolling higher well into the long term.

The company’s latest financials released last week showed group revenues, at constant exchange rates, edge just 1% higher in July-September, to £6.51bn. Although pharmaceutical and vaccine sales in Europe rose 5%, and in the US and Japan by 2%, a 9% drop in its Emerging Markets and Asia Pacific division during the period resulted in a flat on-year performance.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Plummeting sales in China, which have fallen 61% since bribery allegations materialised earlier this year, was cited as a major factor behind the lack of sales growth. The company says that the crisis was caused by a handful of rogue operators, and that it is fully co-operating with authorities in the ongoing investigation, although it admits that “it is still too early for us to quantify the longer-term impact of the investigation on our performance in China.”

Still, I believe that, given the importance of GlaxoSmithKline as a major healthcare provider in the country, the current standoff with Beijing will prove nothing more than a temporary hiccup in the firm’s exciting growth story there. I fully expect the firm likely to emerge with nothing more than a slap on the wrist.

And looking at the firm’s wider operations, I reckon that a bubbly product pipeline in hot growth areas — which saw four approvals and three further US Food and Drug Administration filings during quarter three — is set to underpin exceptional earnings, and thus dividend, progression looking ahead.

GlaxoSmithKline’s expected 4.5% annual dividend per share growth for 2013, to 77.3p, results in a chunky dividend yield of 4.9%. This compares extremely well with a forward average of 2.4% for the entire pharmaceuticals and biotechnology sphere, as well as the corresponding readout of 3.1% for the FTSE 100.

And City analysts expect the pharma giant’s dividend to rise a further 6.5% next year, to 82.3p per share, a figure that currently translates to a 5.2% dividend yield.

Amazing Nerd Stock smashes FTSE with 1,346% gains

What makes this company so extraordinary?

It has a cult-like following of nerdy fans who tend to spend lots of money…

potentially handing investors market-beating gains in any economy.

Though past performance does not guarantee future results, last year, this amazing company saw:

  • Double-digit revenue growth - to a total £470,800,000
  • Profits explode 46%
  • Insiders buying a monster £492,000 of shares

…Setting investors up for - what could be - another decade of spectacular returns.

Want to consider joining them?

Then grab this special report: ‘One Top Growth Stock from The Motley Fool’ which includes both the risks and opportunities.

Secure your FREE copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Are shares like Tesco a safe haven for investors?

Christopher Ruane sees a lot to like about Tesco shares. But does he see them as a safe heaven in…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

The 2025 stock market sell-off could be a once-in-a-decade opportunity to build wealth in an ISA

If a long-term investor has cash sitting in an investment ISA, now could be a good time to put some…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Is now a good time to start buying shares?

Stock market turbulence can be alarming, but it can also offer opportunity. Our writer considers whether now could be the…

Read more »

Investing Articles

Hunting for passive income? These falling insurance giants offer 10% yields

The UK insurance sector is typically a good place to look for attractive dividend yields. Dr James Fox details two…

Read more »

Investing Articles

Considering a Stocks and Shares ISA this April? Avoid these mistakes!

When opening a Stocks and Shares ISA for the first time, it's easy to fall foul of some costly mistakes.…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With global markets down 10%+ investors should remember this legendary quote from Warren Buffett

Warren Buffett is the greatest investor of all time. And he says that the best time to buy shares is…

Read more »

Investing Articles

I asked ChatGPT for the best safe havens in the FTSE 100 amid Trump’s tariffs 

Our writer isn't convinced by the answers that AI assistant ChatGPT rattled off when asked about solid FTSE 100 defensive…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 world-class shares to consider buying in the market sell-off

Looking for blue-chip shares to buy amid the market chaos? Here are two high-quality businesses that Edward Sheldon sees potential…

Read more »